First Line Treatment for Advanced or Metastatic Pancreatic Cancer

IRB# 15588
Serial Measurements of Molecular and Architectural Responses to Therapy

IRB# 17094
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

IRB# 23124
A Phase Ib/2 Randomized Study of AVB-S6-500 plus Nab-Paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma

IRB# 23316
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

IRB# 25336
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

IRB# 25637
Part 3 Arm B: Randomized Phase 2 Study of Gemcitabine/Nab-Paclitaxel Plus 9-ING-41 in Patients with Previously Untreated Metastatic Pancreatic Cancer

IRB# 25366
A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumors Malignancies with KRAS G12D

Cross-Disease Trials:

IRB# 20679
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

IRB# 24931
Legend: LB1908 PI Maziarz

IRB# 25336
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multicentre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
GI Pancreatic - Metastatic

Localized

- NeoAdjuvant
  - IRB #19211: A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
- Adjuvant
  - IRB #21614: NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A NeoAdjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.
  - IRB# 24549: APOLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  - IRB# 17751: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

KEY

- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
GI Pancreatic - Metastatic

Quality Improvement Trials:

IRB # 22619: A Phase II Trial of Pre-operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy

IRB# 22413 Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result